1. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma. Issue 1 (February 2018) Authors: Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; Hutchins, Laura; Linette, Gerald; Triozzi, Pierre; Tan, Marcus C.B.; Brown, Russell E.; Nemunaitis, John; Whitman, Eric; Windham, Christopher; Lutzky, Jose; Downey, Gerald F.; Batty, Nicolas; Amatruda, Thomas Journal: Melanoma research Issue: Volume 28:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗